• 1\. Sign the written informed consent voluntarily;

• 2\. Age ≥ 18, ≤ 75, male or female;

• 3.Expected life ≥ 3 months

• 4\. The physical condition score of the Eastern Tumor Cooperative Organization (ECOG) is 0-2;

• 5.Biopsy sample or pathological wax slice test (within 1 year before signing the informed consent): target test positive

• 6\. According to RECIST v1.1 solid tumor evaluation criteria, there is at least one measurable lesion;

• 7\. Patients with recurrent/metastatic nasopharyngeal carcinoma who have received second-line or above system treatment failure in the past (Recurrence of nasopharyngeal carcinoma: nasopharyngeal carcinoma confirmed by pathology, after radical radiotherapy, the clinical tumor disappears completely, and after 6 months of treatment, local tumors with the same pathological type as the original tumor reappear; metastasis of nasopharyngeal carcinoma: tumor cells transfer from the primary site to distant organs through various ways, such as blood and lymph, and form tumor metastasis focus);

• 8\. It is possible to establish a single blood collection or venous blood collection channel, and there is no other blood cell separation contraindication;

• 9\. It has sufficient organ and bone marrow functions, as defined below

⁃ routine blood test

⁃ Neutrophil count (NEUT #) ≥ 1.0 × 10\^9/L

⁃ Platelet count (PLT) ≥ 80 × 10\^9/L

⁃ Hemoglobin concentration ≥ 90g/L

⁃ Liver function: subjects without liver metastasis

⁃ Aspartate aminotransferase (AST) ≤ 2.5 × Upper limit of normal value (ULN)

⁃ Alanine aminotransferase (ALT) ≤ 2.5 × Upper limit of normal value (ULN)

⁃ Total bilirubin (TBIL) ≤ 1.5 × ULN

⁃ Liver function: subjects with liver metastasis

⁃ Aspartate aminotransferase (AST) ≤ 5 × Upper limit of normal value (ULN)

⁃ Alanine aminotransferase (ALT) ≤ 5 × Upper limit of normal value (ULN)

⁃ Liver function: subjects with liver metastasis or Gilbert syndrome

⁃ Total bilirubin (TBIL) ≤ 2 × ULN

⁃ renal function

⁃ Creatinine clearance rate (CCR) ≥ 50mL/min

⁃ Coagulation function

⁃ International normalized ratio (INR) ≤ 1.5 × ULN

⁃ Activated partial thromboplastin event (APTT) ≤ 1.5 × ULN

• 10\. Toxic side effects left by early anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.) ≤ Level 1 (CTCAE5.0);

• 11\. During the study period and within 6 months after the last administration, subjects with fertility (male or female) must take effective medical contraceptive measures. Female subjects of childbearing age must have a pregnancy test within 72 hours before the first administration, and the result is negative.